Search Results

Nine-Month PLATINUM QCA Data Presented for Boston Scientific's Promus Element

September 21, 2010—Boston Scientific Corporation (Natick, MA) announced that data from its PLATINUM QCA study were presented by Principal Investigator Ian T. Meredith, MD, at the Transcatheter Cardiovascular Therapeutics scientific symposium in Washington, DC. PLATINUM QCA is designed to evaluate the company's Promus Element everolimus-eluting platinum chromium coronary stent. The results provided 30-day and 9-month clinical outcomes and 9-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the Promus Element stent.

One-Year REPRISE II Data Published for Boston Scientific's Lotus TAVR Device in High-Risk Patients With Severe Aortic Stenosis

February 15, 2016—Ian T. Meredith, MD, et al published the 1-year outcomes of the 120 patients enrolled in the REPRISE II study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2016;9:376–384). REPRISE II is evaluating the fully repositionable and retrievable Lotus valve (Boston Scientific Corporation), which is designed to facilitate accurate positioning, early valve function, and hemodynamic stability during deployment, and to minimize paravalvular regurgitation in patients undergoing transcatheter aortic valve replacement.

Three-Year RESOLUTE Data Presented for Medtronic's Zotarolimus-Eluting Stent

September 21, 2009—Medtronic, Inc. (Minneapolis, MN) announced that new clinical data show strong and sustained efficacy and safety of the company's Resolute zotarolimus-eluting coronary stent in long-term patient follow-up.

Three-Year RESOLUTE Data Presented for Medtronic's Zotarolimus-Eluting Stent

September 21, 2009—Medtronic, Inc. (Minneapolis, MN) announced that new clinical data show the strong and sustained efficacy and safety of the company's Resolute zotarolimus-eluting coronary stent in long-term patient follow-up.

PLATINUM Small Vessel Data Support Boston Scientific's Promus Element Stent

May 20, 2011—Boston Scientific Corporation (Natick, MA) announced that 12-month results from its PLATINUM Small Vessel study demonstrated excellent safety and effectiveness outcomes for the 2.25-mm Promus Element everolimus-eluting platinum chromium stent system in treating small-vessel coronary disease.

Enrollment Begins in REMEDEE Trial of OrbusNeich's Combo DES

December 1, 2009—OrbusNeich, Inc. (Fort Lauderdale, FL) announced the initiation of patient enrollment in the REMEDEE (Randomized Evaluation of an Abluminal Sirolimus-Coated Bio-Engineered Stent) clinical trial of the company's Combo bioengineered sirolimus-eluting stent.

Boston Scientific's Lotus TAVR System Meets REPRISE II 30-Day Primary Performance Endpoint

October 31, 2013—Boston Scientific Corporation (Natick, MA) announced that the company's Lotus transcatheter aortic valve replacement (TAVR) system met a key performance measure in the treatment of symptomatic patients with severe aortic valve stenosis considered at high risk for surgical valve replacement.

EVOLVE Data Presented for Boston Scientific's Synergy Bioabsorbable DES

November 11, 2011—Boston Scientific Corporation (Natick, MA) announced that results from the EVOLVE first-human-use trial demonstrated the noninferiority of the company’s Synergy everolimus-eluting stent system compared to its Promus Element everolimus-eluting stent system in treating de novo coronary artery lesions.

Boston Scientific's Lotus TAVR System Receives CE Mark Approval

October 28, 2013—Boston Scientific Corporation (Natick, MA) announced European CE Mark approval for the Lotus valve system for transcatheter aortic valve replacement (TAVR) as a treatment alternative for patients with severe aortic stenosis at high risk for surgical valve replacement.